SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 30, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, today announced that the company has submitted a New Drug Application (NDA) for Zensana(TM) (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and post-operative induced nausea and vomiting.
